Sanofi's blockbuster skin and asthma drug Dupixent significantly reduced itching in patients with chronic hives, paving the way for the resubmission of the drug for this condition.

The treatment resulted in an almost 50% decrease in scores relating to itching and hives in a late-stage trial, confirming results from an earlier study, Sanofi said Wednesday.